Presentation (CTI)

OBJECTIVES: The objective of this analysis was to conduct a cost analysis of hemostatic patch utilization and rescue therapy use from a recently completed prospective, randomized pivotal clinical investigation comparing the safety and performance of GATT-Patch (ETHIZIA) with TachoSil to control minimal, mild or moderate bleeding during elective open liver surgery.
METHODS: The cost analysis included 87 patients randomized to ETHIZIA and 43 patients randomized to TachoSil (ClinicalTrials.gov ID: NCT05385952). Hemostatic patch product utilization was estimated based on the median patch size required per square centimeter of bleeding surface. Rescue therapy used was determined based on investigator-reported use of product such as Surgiflo, Floseal and sutures. Cost of product used was determined by multiplying the total amount of patches used by the unit cost per patch, assuming no product wastage. Additionally, the costs of rescue therapies were derived from publicly accessible sources. A one-way sensitivity analysis was conducted by varying the unit cost of all items and the amount of hemostatic product used by ±10%.
RESULTS: The average cost per patient treated with Ethizia was $425.13 compared to $605.49 for patients treated with Tachosil, resulting in an estimated cost savings of $180.35 for Ethizia use. The cost differential was largely driven by a reduction in amount of product used. Fewer patients treated with Ethizia required rescue therapies, though it did not substantially impact overall costs due to relatively low unit cost.One-way sensitivity analyses further assessed the robustness of the results. When varying the unit costs for all outcomes by ±10%, the cost differential ranged between $162.32 to $198.39. Additionally, varying the amount of Ethizia product used by ±10% resulted in a cost differential between $138.35 to $222.35.
CONCLUSIONS: Use of ETHIZIA to control bleeding in the open‑liver RCT was associated with cost savings compared to Tachosil.